1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

BioNotebook: Alector, Dimension, Discovery Labs, BioMarin/Clovis, Array, CEL-SCI, Otonomy, GlobeImmune

 
• By Mandy Jackson

Alector, Dimension raise Series A rounds; Discovery Labs sells $50m in stock; BioMarin, Clovis start PARP inhibitor studies; Array takes ARRY-502 into Phase III; CEL-SCI seeks arbitration with CRO; Otonomy buys tinnitus IP; and GlobeImmune withdraws IPO.

Alector, Dimension raise Series A rounds; Discovery Labs sells $50m in stock; BioMarin, Clovis start PARP inhibitor studies; Array takes ARRY-502 into Phase III; CEL-SCI seeks arbitration with CRO; Otonomy buys tinnitus IP; and GlobeImmune withdraws IPO.

Alector raises Series A cash, taps Adimab antibody discovery engine

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

More from Therapy Areas

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.